Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from HeraMED Ltd. ( (AU:HMD) ) is now available.
HeraMED Limited has secured firm commitments to raise A$3.2 million through a two‑tranche placement of 80 million new shares at A$0.04 each, a roughly 7% discount to its last closing price, with support from new institutional and sophisticated investors as well as existing shareholders. The funds will be used to bolster working capital and accelerate the commercial deployment, pilots and integration of its HeraCARE digital maternity platform into major health systems, private clinics and multiple partner platforms in the U.S., Australia and Europe, building on initial commercial agreements with Lee Health and Philips and reinforcing the company’s push for broader scale and stronger market positioning in women’s digital health.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
More about HeraMED Ltd.
HeraMED Limited (ASX: HMD) is an innovative medical data and technology company focused on digital maternity and women’s health. It offers a hybrid maternity care platform built around its proprietary HeraCARE ecosystem and HeraBEAT in‑home foetal and maternal heart rate monitor, combining hardware, cloud computing, artificial intelligence and big data to support prenatal and postpartum care for large health systems, private clinics and other healthcare providers across the U.S., Australia and Europe.
Average Trading Volume: 986,359
Technical Sentiment Signal: Buy
Current Market Cap: A$46.02M
For an in-depth examination of HMD stock, go to TipRanks’ Overview page.